Neoplasia/BPH

	Mismatch Repair Pathway, MLH1, MSH2 and Mutations in Prostate Cancer. Int J Surg Pathol Himanshu, Osama MA, Singh L, Mir RA, Batra A, Sahoo RK, Nayak B, Seth A, Iyer VK. PMID: 42852818 [PubMed - as supplied by publisher]
	Associations between advanced lung cancer inflammation index score and kidney outcomes in intensive care unit patients with diabetes: A retrospective cohort study. J Int Med Res Wang X, Su T, Lu Y, Feng LH. PMID: 42852716 [PubMed - indexed for MEDLINE]
	Effects of Acupoint Application on Lower Urinary Tract Symptoms in Patients Undergoing Intravesical Instillation After Bladder Cancer Surgery: A Randomized Crossover Exploratory Study. Pain Res Manag Shi L, Chen C, Li L, Chen J, Zhang Y, Li J, Xu Z, Lu D, Ma Y, Feng Y, Jin C, Wang Y. PMID: 42852700 [PubMed - indexed for MEDLINE]
	Retrospective log-based quality assurance of real-time MLC adaptation on a helical tomotherapy platform. J Appl Clin Med Phys Crowe SB, Kairn T. PMID: 42851036 [PubMed - indexed for MEDLINE]
	Nitro-Substituted Azo Dyes as Anti-Prostate Cancer Candidates and Nonlinear Optical Properties: Synthesis and In Silico Studies. J Fluoresc Hameed MH, Dhumad AM, Emshary CA, Hassan QMA, Sultan HA. PMID: 42850376 [PubMed - as supplied by publisher]
	Refining biopsy strategies stratified by PI-RADS score in men: a systematic review and network meta-analysis. Nat Commun Wu Q, Chen B, Chen Z, Tu X, Wang J, Jiang J, Zheng L, He C, Bao Y, Tang B, Wei Q. PMID: 42850231 [PubMed - indexed for MEDLINE]
	Effect of nefopam on postoperative catheter-related bladder discomfort after transurethral resection of the bladder under general anesthesia: A randomized controlled trial. J Int Med Res Yeom JY, Kim YU, Kim J, Min J, Ma H, Choi E. PMID: 42850220 [PubMed - indexed for MEDLINE]
	Log Odds of Positive Lymph Nodes as a Novel Prognostic Predictor for Bladder Cancer: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer Vaezi A, Mossavarali S, Raznahan M, Haddad M, Salari A, Nowroozi MR, Amini E. PMID: 42850160 [PubMed - as supplied by publisher]
	Preclinical Evaluation on the Radiohybrid Tandem [(18)F]La- and [(225)Ac]Ac-rhPSMA-10.1 for Targeted Î±-Therapy of Prostate Cancer. J Nucl Med Sun B, Werner D, Ni J, Weidle S, Steiger K, Seyfi S, Kossatz S, Eiber M, Morgenstern A, Bruchertseifer F, Chilug EL, Weber WA, D'Alessandria C, Wurzer A. PMID: 42850042 [PubMed - as supplied by publisher]
	A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma. ESMO Open Rini BI, Powles T, Tomczak P, Shin SJ, Guo J, Molina-Cerrillo J, Ren X, Lee JL, Wysocki PJ, Puente J, Basu A, Mar N, Bernhard S, Khan O, Ha J, Colley L, Prizant H, Albiges L. PMID: 42849355 [PubMed - as supplied by publisher]
	From validation trials to clinical reality: implementing AI-supported prostate MRI pathways in the NHS. Br J Nurs Adesuyi A, Singh S, Ankur M. PMID: 42848705 [PubMed - indexed for MEDLINE]
	Implementation and evaluation of a nurse-led clinic for men referred with suspected prostate cancer. Br J Nurs Teodorowski P, Thomson J, McInnes M, Hibberd C, McFarland A, Gadsby E. PMID: 42848699 [PubMed - indexed for MEDLINE]
	Development and Validation of a Tool to Measure Documented Health Care Encounter Time. JAMA Netw Open Chow R, Bayrakdarian S, Gojsevic O, MacMillan E, Balboni T, Bowen J, Bruera E, Chan RJ, Gupta A, Hart NH, Hoskin P, Hui D, Iihara H, Jefford M, Lee SF, Riechelmann R, Rugo HS, Ruhlmann CH, Simone CB 2nd, Wong HCY, Zimmermann C, Chung H, Richards GC, Heneghan C, Leigh J, MASCC Emerging Toxicities Study Group. PMID: 42848401 [PubMed - indexed for MEDLINE]
	Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial. JAMA Oncol Qie Y, Jia K, Huang S, Zhao J, Xue Z, Guo S, Zhang T, Wu Z, Shen C, Hu H. PMID: 42848391 [PubMed - as supplied by publisher]
	Clinical efficacy and safety of second-line cabozantinib after first-line immune checkpoint inhibitor-based combinations in metastatic renal cell carcinoma: a multicenter retrospective study. Int J Clin Oncol Matsukawa A, Kato T, Oki M, Takao T, Inoki L, Sato M, Okada K, Maekawa T, Imanaka T, Nakayama J, Tomiyama E, Nagahara A, Ishizuya Y, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Nakayama M, Takayama H, Ono Y, Takada S, Nishimura K, Fujita K, Imamura R, Nonomura N. PMID: 42848309 [PubMed - as supplied by publisher]
	Summary of Research:Â Health-Related Quality-of-Life Profile and Clinical Outcomes in First-Line Advanced Renal Cell Carcinoma: A Modeling Analysis Based on the CheckMate 9ER Study. Adv Ther Cella D, Derosa M, Floden L, Giles RH, Lothgren M, Ogareva A, Powles T, Purnajo I, Choueiri TK, Bergerot C, Motzer RJ, Bedke J. PMID: 42848188 [PubMed - as supplied by publisher]
	Retroperitoneal lymph node dissection for isolated node recurrence of renal cell carcinoma after nephrectomy: a systematic review. World J Urol Costa Silva A, Clarke N, Gulamhusein A. PMID: 42848085 [PubMed - indexed for MEDLINE]
	Exploratory Analysis of Peri-Prostatic Adipose Tissue Radiomics Features and Their Potential to Predict Prostate Cancer Diagnosis: Results From a UK Biobank Study. Prostate O'Neill A, O'Keeffe R, Winter S, Dorrian J, Gaunt TR, Guönason V, Travis RC, Martin RM, Allott EH, Leech M. PMID: 42847696 [PubMed - as supplied by publisher]
	Characteristics and Treatment Patterns of Patients with Muscle-Invasive Bladder Cancer in the United States: A Real-World Cohort Study. Pragmat Obs Res Gore JL, Thompson A, Kelkar SS, Chirikov V, Kamat S, Quan W, Donnowitz K, Young C, Nimke D, Quicquaro CM, Willmon CL, Pednekar P. PMID: 42846494 [PubMed]
	Immunosuppressive cell populations as potential drivers of extrinsic immune checkpoint inhibition resistance in clear cell renal cell carcinoma. Oncol Rev Temuri UH. PMID: 42846110 [PubMed]

Articles 1 - 20 / 191914

Page 1 of 9596



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy